Sutro Biopharma (STRO) Revenue (2017 - 2025)

Sutro Biopharma's Revenue history runs 9 years deep, the most recent figure standing at $6.6 million for Q4 2025.

• In Q4 2025, Revenue fell 55.43% year-over-year to $6.6 million; the TTM figure through Dec 2025 stood at $85.7 million (up 58.37% YoY), while the FY2025 annual figure was $102.5 million, up 65.18% from the prior year.
• Revenue came in at $6.6 million for Q4 2025 at Sutro Biopharma, down from $9.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $113.7 million in Q4 2023 to a low of $5.7 million in Q1 2025.
• A 5-year average of $21.2 million and a median of $12.8 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue jumped 1217.44% in 2023 and sank 86.98% in 2024, its largest moves.
• Sutro Biopharma's Revenue stood at $10.7 million in 2021, then fell by 18.98% to $8.6 million in 2022, then surged by 1217.44% to $113.7 million in 2023, then tumbled by 86.98% to $14.8 million in 2024, then plunged by 55.43% to $6.6 million in 2025.
• According to Business Quant data, Revenue over the past three periods registered $6.6 million, $9.7 million, and $63.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison